In the march towards disease-modifying treatments for Alzheimer disease, immunotherapy with antibodies against amyloid-β protein is furthest along in human trials. The news that Biogen’s aducanumab showed no cognitive benefit in phase III trials requires careful analysis of what went wrong and how to position anti-amyloid agents among other therapeutic approaches.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Repurposing non-pharmacological interventions for Alzheimer's disease through link prediction on biomedical literature
Scientific Reports Open Access 15 April 2024
-
3D convolutional neural networks uncover modality-specific brain-imaging predictors for Alzheimer’s disease sub-scores
Brain Informatics Open Access 04 February 2024
-
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Alzheimer's Research & Therapy Open Access 18 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Selkoe, D. J. Preventing Alzheimer’s disease. Science 337, 1488–1492 (2012).
Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl Med. 3, 89ra57 (2011).
Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin? Sci. Transl Med. 6, 228fs13 (2014).
Butovsky, O. & Weiner, H. L. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19, 622–623 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.J.S. is a consultant for E-Scape Bio and Prothena.
Rights and permissions
About this article
Cite this article
Selkoe, D.J. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol 15, 365–366 (2019). https://doi.org/10.1038/s41582-019-0205-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0205-1
This article is cited by
-
3D convolutional neural networks uncover modality-specific brain-imaging predictors for Alzheimer’s disease sub-scores
Brain Informatics (2024)
-
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Alzheimer's Research & Therapy (2024)
-
Repurposing non-pharmacological interventions for Alzheimer's disease through link prediction on biomedical literature
Scientific Reports (2024)
-
Tetramethylpyrazine Nitrone Promotes the Clearance of Alpha-Synuclein via Nrf2-Mediated Ubiquitin–Proteasome System Activation
NeuroMolecular Medicine (2024)
-
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial
Alzheimer's Research & Therapy (2023)